EMUC23: What can we learn from adverse events?
Adverse events can positively transform new approaches in patient management. How? By applying lessons learned, and using these as a cornerstone for safer pathways. The upcoming 15th European Multidisciplinary Congress on Urological Cancers (EMUC23) will have a Plenary Session dedicated to insights gained from adverse events.
In this article, esteemed urologist and Session Chair, Prof. Axel Bex (GB) will provide a sneak peek of Plenary Session 4: Learning points from morbidity and mortality.
A “Nightmare Session” with a twist?
“In clinical practice, morbidity and mortality reviews serve to uncover what went wrong. These reviews give crucial insights on what can be prevented to improve the safety of our patients,” stated Prof. Bex.
He added that Plenary Session 4 will focus on incidents and their acute management. The session is designed with a high educational value in mind; not only focusing on what could have been avoided, but also on what can be done and what can be improved.
The session will present prostate, bladder, and renal cell cancer cases that shaped positive changes in patient management. During the case presentations, the speakers will provide information on what actions they took to ensure a safe pathway. The panel will examine and deliberate the implemented approaches and put these into a general perspective.
Prof. Bex disclosed, “The speakers carefully and thoroughly selected cases from a learning perspective. These cases will involve multidisciplinary complexity imbued with invaluable knowledge gained.”
Unite to treat
In ensuring a safe pathway, what does collaboration among diverse specialists mean for uro-oncological patients? According to Prof. Bex, it is essential that these patients are managed with an interdisciplinary approach because, at present, advanced cases are rarely managed by one specialty alone.
He added that management may include neoadjuvant therapy, radiotherapy, palliative care, support from hepatobiliary and cardiovascular surgery, as well as, upfront systemic therapy. “Pathways have to be designed to take care of every aspect that a patient may encounter so they receive the care they require,” concluded Prof. Bex.
Prof. Bex will lead Plenary Session 4 together with fellow renowned experts and co-chairs, medical oncologist Prof. Ursula Vogl (CH), and radiation oncologist Prof. Thomas Zilli (CH). They will be joined by the distinguished Mr. Bertie Leigh (GB), a veteran of healthcare and medical law.
More about the session and EMUC23
The EMUC congress is the only uro-onco event in Europe centred on the synergy of diverse medical specialties. Its latest edition, EMUC23, will take place from 2 to 5 November 2023 in Marseille, France. Plenary Session 4 will commence on 3 November 2023.
Prof. Camillo Porta (IT) representing the European Society for Medical Oncology (ESMO); Prof. Peter Hoskin (GB) on behalf of the European SocieTy for Radiotherapy and Oncology (ESTRO); and EAU Secretary General Prof. Arnulf Stenzl (EAU) will spearhead the congress as the steering committee members.
At EMUC23, expect a stellar scientific programme comprised of pioneering developments in the prevention, diagnosis, and treatment of genito-urinary (GU) cancers; critical yet riveting debates; and eye-opening insights from a multidisciplinary standpoint.
To secure your place at the congress and to benefit from the best rates, register now. We look forward to welcoming you at EMUC23!
